3003 Prognostic value of on-treatment serum neurofilament light chain for neT2 lesions relapsing MS patients: pooled analysis of ASCLEPIOS I/II

• Jeannette Lechner-Scott,
• Wenjia Wei,
• Heinz Wiendl,
• Xavier Montalban,
• Stephen L Hauser,
• Tjalf Ziemssen,
• Douglas L Arnold,
• Enrique Alvarez,
• Tobias Derfuss,
• Thomas P Leist,
• Alit Bhatt,
• Ibolya Boer

Affiliations

Jeannette Lechner-Scott

10Department of Neurology, John Hunter Hospital, New Lamberton Heights, NSW, Australia

Wenjia Wei

Department of Epidemiology, Epidemiology, Biostatistics & Prevention Institute, University of Zurich, Zurich, Switzerland

Heinz Wiendl

Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Nordrhein-Westfalen, Germany

Xavier Montalban

12Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain

Stephen L Hauser

5UCSF Weill Institute for Neuroscience, University of California, San Francisco, California, USA

Tjalf Ziemssen

3Department of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic, University Hospital of Dresden, Fetscherstr. 74, 01307, Dresden, Saxony Land, Germany

Douglas L Arnold

7NeuroRx Research and Montréal Neurological Institute, McGill University, Montreal, QC, Canada

Enrique Alvarez

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Tobias Derfuss

2 Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedicine, University Hospital and University of Basel, Basel, Switzerland

Thomas P Leist

4Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Alit Bhatt

10Novartis Healthcare Pvt Ltd, Hyderabad, India

Ibolya Boer

11Novartis Pharma AG, Basel, Switzerland